Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
Eli Lilly and Company
Athimalaipet V Ramanan; Pierre Quartier; Nami Okamoto; Ivan Foeldvari; Alberto Spindler; Šárka Fingerhutová; Jordi Antón; Zhongkai Wang; Gabriella Meszaros; Joana Araújo; Ran Liao; Stuart Keller; Hermine I Brunner; Nicolino Ruperto; JUVE-BASIS investigators; Paediatric Rheumatology International Trials Organisation